Adds three new directors with deep expertise across biopharma and life sciences SOMERSET, N.J. / Feb 20, 2025 / Business Wire / Catalent, Inc. , the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership.... Read More

Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership SOMERSET, N.J. & COPENHAGEN, Denmark / Dec 18, 2024 / Business Wire / Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that... Read More

Transaction Expected to Close in the Coming Days SOMERSET, N.J. & COPENHAGEN, Denmark / Dec 14, 2024 / Business Wire / Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the companies have fulfilled all regulatory closing conditions for their... Read More

Transaction Expected to Close Towards the End of Calendar Year 2024 SOMERSET, N.J. & COPENHAGEN, Denmark / Dec 06, 2024 / Business Wire / Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the European Commission (EC) has granted unconditional... Read More

Q1'25 net revenue of $1.02 billion increased 4% as reported and in constant currency (1) , compared to Q1'24. Q1'25 net revenue, excluding COVID revenue of ~$30 million in Q1’25 and ~$100 million in Q1'24, increased 13% compared to Q1'24. Q1'25 net loss of $(129) million. Q1'25 Adjusted EBITDA (1) of $125 million increased 11% as reported, or 10% in constant currency, compared to Q1'24. (1) See "Non-GAAP Financial Measures"... Read More

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J. / Oct 21, 2024 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers: To Catalent’s... Read More

SOMERSET, N.J. / Oct 14, 2024 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium,... Read More

Q4'24 net revenue of $1.30 billion increased 23% as reported, or 24% in constant currency, compared to Q4'23. Organic, constant-currency net revenue increased 24%, compared to Q4'23. Q4'24 net revenue, excluding COVID-related revenue of ~$70 million in Q4’23 and ~$30 million in Q4’24, increased 29% compared to Q4'23. Fiscal 2024 net revenue of $4.38 billion increased 3% as reported, or 2% in constant currency, compared to... Read More

Expansion adds more temperature-controlled storage and dedicated space for FastChain ® demand-led supply service SOMERSET, N.J. / Jul 16, 2024 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansion... Read More

SOMERSET, N.J. / May 29, 2024 / Business Wire / Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding shares... Read More

Q3'24 net revenue of $1.07 billion increased 4% as reported, or 3% in constant currency (1) , compared to Q3'23. Q3'24 net revenue, excluding COVID-related revenue of ~$120 million in Q3’23 and ~$60 million in Q3’24, increased 11% compared to Q3'23. Q3'24 net loss of $(101) million compared to $(227) million of net loss in Q3'23. Q3'24 Adjusted EBITDA (1) of $163 million increased 55% as reported, or 53% in constant... Read More

Commits to reducing Scope 1 and 2 greenhouse gas emissions by 42% from its 2022 baseline by 2030, with commitment to ensuring 70% of supplier emissions have science-based targets by end of fiscal 2028. Implemented ISO-certified environmental management systems at 24 locations, which account for more than 70% of the company’s overall energy use. Continued to build social impact through increased diversity and inclusion... Read More

Q2'24 net revenue of $1.03 billion decreased 10% as reported, or 11% in constant currency (1) , compared to Q2'23. Q2'24 net revenue, excluding COVID-related revenue of ~$260 million in Q2’23 and ~$75 million in Q2’24, increased 8% compared to Q2'23. Q2'24 net loss of $(204) million compared to $81 million of net income in Q2'23 due primarily to a decline in COVID-related demand. Q2'24 Adjusted EBITDA (1) of $124 million... Read More

Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024 COPENHAGEN, Denmark & SOMERSET, N.J. / Feb 05, 2024 / Business Wire / Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for... Read More

SOMERSET, N.J. / Jan 26, 2024 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the second quarter of fiscal year 2024 ended December 31, 2023, before the market open on Friday, February 9, 2024. The Company’s management will host a webcast to discuss the results at 8:15 a.m.... Read More

New targets approved by Science Based Targets initiative (SBTi) SOMERSET, N.J. / Jan 25, 2024 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced its targets to reduce greenhouse gas emissions (Scope 1 and 2) by 42% by 2030. The company also committed to engaging with its suppliers, of purchased goods and services,... Read More

SOMERSET, N.J. / Jan 04, 2024 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executive leadership team will participate at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 5:15 p.m. ET. A live webcast of the presentation will be accessible at http://investor.catalent.com... Read More

SOMERSET, N.J. / Dec 19, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that its wholly owned subsidiary, Catalent Pharma Solutions, Inc., as borrower, and certain other wholly owned subsidiaries of Catalent, entered into an amendment, dated as of December 19, 2023, to its existing credit agreement for the... Read More

SOMERSET, N.J. / Dec 15, 2023 / Business Wire / Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT) announced today that the Company has received written notification (“Notice”) from the New York Stock Exchange (“NYSE”) that it has officially regained compliance with the NYSE continued listing standards. Following the filing by the Company on December 8, 2023 of its Annual Report on Form 10-K for the year ended June... Read More

Q1'24 net revenue of $982 million decreased 4% as reported, or 6% in constant currency (1) , compared to Q1'23. Organic, constant-currency net revenue decreased by 8%, compared to Q1'23. Q1'24 net revenue, excluding COVID revenue of ~$185 million in Q1’23 and ~$100 million in Q1’24, increased 5% compared to Q1'23. Q1'24 net loss of $(715) million, includes non-cash goodwill impairment charges of $700 million. Q1'24 Adjusted... Read More

SOMERSET, N.J. / Oct 31, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release preliminary financial results for the first quarter of fiscal year 2024 ended September 30, 2023, before the market open on Wednesday, November 15, 2023. Catalent’s management will host a webcast to discuss the... Read More

SOMERSET, N.J. / Sep 18, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent’s Biologics segment, effective September 25, 2023. Mr. McErlane joins Catalent from Lonza, where he served as senior vice president and business unit head for Lonza’s Bioscience... Read More

SOMERSET, N.J. / Sep 15, 2023 / Business Wire / Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, on September 14, 2023, it received a notice (the “NYSE Notice”) from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with the NYSE’s continued listing requirements under the... Read More

SOMERSET, N.J. / Sep 07, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executive leadership team will participate at two upcoming investor conferences. On September 12, 2023, at 10:50 a.m. ET, the Company will present at the Morgan Stanley 21 st Annual Global Healthcare Conference. On... Read More

Adding Four New Independent Directors Appoints John Greisch as Executive Chair Establishes New Strategic and Operational Review Committee of the Board Enters into Cooperation Agreement with Elliott Investment Management L.P. SOMERSET, N.J. / Aug 29, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better biopharmaceutical treatments for patients worldwide, today... Read More

Q4'23 net revenue of $1.07 billion decreased (17)% as reported, or (17)% in constant currency, compared to Q4'22. Organic, constant-currency net revenue decreased (19)%, compared to Q4'22. Fiscal 2023 net revenue of $4.28 billion decreased (11)% as reported, or (9)% in constant currency, compared to fiscal 2022. Organic, constant-currency net revenue decreased (11)% compared to FY'22. Q4'23 net loss of $(86) million and... Read More

SOMERSET, N.J. / Aug 22, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the fourth quarter of fiscal year 2023 ended June 30, 2023, before the market open on Tuesday, August 29, 2023. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET... Read More

SOMERSET, N.J. / Aug 01, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Lisa Evoli has been named Senior Vice President & Chief Human Resources Officer, effective immediately. Ms. Evoli joins Catalent from Integra Lifesciences, a global medical technology company based in Princeton, New Jersey. “Lisa is a... Read More

SOMERSET, N.J. / Jun 20, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Matti Masanovich has been named Senior Vice President & Chief Financial Officer, effective July 5, 2023. Prior to joining Catalent, Mr. Masanovich served as Executive Vice President & Chief Financial Officer of Tenneco Automotive until... Read More

SOMERSET, N.J. / Jun 13, 2023 / Business Wire / Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT) announced today that the Company has received written notification (“Notice”) from the New York Stock Exchange (“NYSE”) that it has officially regained compliance with the NYSE continued listing standards. Following the filing by the Company on June 12, 2023 of its Quarterly Report on Form 10-Q for the three and nine... Read More

Q3'23 net revenue of $1.04 billion decreased 19% as reported, or 17% in constant currency (1) , compared to Q3'22. Organic, constant-currency net revenue decreased by 19%, compared to Q3'22. Q3'23 net loss of $(227) million, including a goodwill impairment of $210 million. Q3'23 Adjusted EBITDA (1) of $105 million decreased 69% as reported, or 68% in constant currency, compared to Q3'22. Updated FY'23 financial guidance... Read More

SOMERSET, N.J. / Jun 09, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the third quarter of fiscal year 2023 ended March 31, 2023, before the market open on Monday, June 12, 2023. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET on... Read More

SOMERSET, N.J. / May 19, 2023 / Business Wire / Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, in light of the circumstances described in the Company’s Notification of Late Filing on Form 12b-25 filed on May 11, 2023 (the “Form 12b-25”) with the Securities and Exchange Commission (the “SEC”); the... Read More

SOMERSET, N.J. / May 12, 2023 / Business Wire / Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that in light of the circumstances described in the Company’s Form 12b-25 filed on May 11, 2023, with the Securities and Exchange Commission, and the Company’s ongoing focus on finalizing its financial... Read More

SOMERSET, N.J. / May 08, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will be delaying the release of its third fiscal quarter results and investor conference call, previously scheduled for Tuesday, May 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with... Read More

SOMERSET, N.J. / May 05, 2023 / Business Wire / Catalent, Inc. (“Catalent”) (NYSE: CTLT) has been notified of an unsolicited “mini-tender offer” by TRC Capital Investment Corporation (“TRC”) to purchase up to 2,000,000 shares of Catalent’s common stock at a price of $42.95 per share in cash. TRC’s offer price is approximately 4.43% lower than the $44.94 closing price of Catalent’s common stock on April 24, 2023, the last... Read More

SOMERSET, N.J. / Apr 14, 2023 / Business Wire / Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced a business update. While complete financial information and operating data for the Company’s third fiscal quarter ended March 31, 2023 are not yet finalized, the Company expects that productivity issues and... Read More

SOMERSET, N.J. / Mar 09, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executive leadership team will participate at two upcoming investor conferences. On March 14, 2023 at 10:45 a.m. ET, the Company will present at the Barclays Global Healthcare Conference. On March 21, 2023, at 12:00 p.m.... Read More

SOMERSET, N.J. / Mar 06, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Sridhar Krishnan, to the newly created position of Vice President, The Catalent Way, where he will lead the company’s operational excellence strategy and spearhead a transformation based on Lean principles, designed to... Read More

SOMERSET, N.J. / Feb 28, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today published its fourth Corporate Responsibility Report for its fiscal year 2022, which ended June 30, 2022. The report highlights Catalent's progress against its previously published targets and commitments in the areas of environmental, social, and... Read More

SOMERSET, N.J. / Feb 13, 2023 / Business Wire / Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary. Mr. Ferraro will be responsible for managing Catalent's global legal and compliance operations. He will be based at the... Read More

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it will release financial results for the second quarter of fiscal year 2023 ended December 31, 2022, before the market open on Tuesday, February 7, 2023. The Company’s management will host a webcast... Read More

RADNOR, Pa. and SOMERSET, N.J. , Jan. 9, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced that it has entered into a multi-year supply and services agreement with Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better... Read More

Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of... Read More

Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will participate at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 at 5:15 p.m. EST. A live webcast of the presentation will be accessible... Read More